November 13th, 2026Testosterone in women: Androgenic adverse events and lab monitoringBlood levels alone cannot confirm safe testosterone dosing. Asking about androgenic effects and allowing months for response are central to care.Read more
November 13th, 2026Testosterone for women: Global consensus and physiologic dosingA global consensus defines what the evidence supports for testosterone in women. Benefits for strength, mood, and cognition lack randomized data.Read more
November 13th, 2026Testosterone physiology in women and the long road to approvalA testosterone patch improved sexual desire in trials but never won US approval. Normal female physiology defines what replacement should target.Read more
November 13th, 2026WHI fallout: How hormone fears stalled testosterone therapy for womenThe WHI never studied testosterone, yet it chilled conversations about every hormone, with lasting consequences for women’s sexual health.Read more
November 13th, 2026How estrogen-centered menopause care sidelined testosterone in womenAs estrogen came to define menopause care, testosterone faded from view, and the oral combination clinicians relied on was never FDA approved.Read more
November 13th, 2026Testosterone in women: Early history of androgen therapyAndrogen therapy for women predates the headlines by decades. Early research showed promise for desire, but long-term safety data never caught up.Read more
November 9th, 2026Mental health, bias, and trauma: Building trust in sexual medicineMental health, bias, and trauma shape sexual health visits, and histories should assess function, not just risk, according to Sameena Rahman, MD. Read more
November 4th, 2026Why has ovarian cancer screening eluded researchers for 4 decades?Samples from a large UK screening trial supported validation of the investigational Evident ovarian cancer test, according to Dawn Mattoon, PhD. Read more